GLUE Monte Rosa Therapeutics Inc

Price (delayed)

$4.17

Market cap

$210.64M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.51

Enterprise value

$151.2M

Highlights
The debt has declined by 2.1% year-on-year
Monte Rosa Therapeutics's EPS has increased by 4.6% from the previous quarter but it has decreased by 3.3% YoY
The quick ratio has dropped by 58% year-on-year and by 6% since the previous quarter
The equity has declined by 37% year-on-year and by 15% since the previous quarter

Key stats

What are the main financial stats of GLUE
Market
Shares outstanding
50.51M
Market cap
$210.64M
Enterprise value
$151.2M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.37
Price to sales (P/S)
235.76
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
142.11
Earnings
Revenue
$1.06M
EBIT
-$134.86M
EBITDA
-$127.89M
Free cash flow
-$69.74M
Per share
EPS
-$2.51
Free cash flow per share
-$1.16
Book value per share
$3.04
Revenue per share
$0.02
TBVPS
$4.43
Balance sheet
Total assets
$266.75M
Total liabilities
$114.23M
Debt
$45.18M
Equity
$152.52M
Working capital
$157.74M
Liquidity
Debt to equity
0.3
Current ratio
4.82
Quick ratio
4.8
Net debt/EBITDA
0.46
Margins
EBITDA margin
-12,020%
Gross margin
100%
Net margin
-12,714.5%
Operating margin
-13,533.7%
Efficiency
Return on assets
-49.1%
Return on equity
-74.1%
Return on invested capital
-66.4%
Return on capital employed
-59.8%
Return on sales
-12,674.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

GLUE stock price

How has the Monte Rosa Therapeutics stock price performed over time
Intraday
-3.47%
1 week
7.2%
1 month
8.88%
1 year
-40.17%
YTD
-26.19%
QTD
11.5%

Financial performance

How have Monte Rosa Therapeutics's revenue and profit performed over time
Revenue
$1.06M
Gross profit
$1.06M
Operating income
-$144M
Net income
-$135.28M
Gross margin
100%
Net margin
-12,714.5%
The operating income has declined by 18% year-on-year
The net income has contracted by 16% YoY

Growth

What is Monte Rosa Therapeutics's growth rate over time

Valuation

What is Monte Rosa Therapeutics stock price valuation
P/E
N/A
P/B
1.37
P/S
235.76
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
142.11
Monte Rosa Therapeutics's EPS has increased by 4.6% from the previous quarter but it has decreased by 3.3% YoY
The equity has declined by 37% year-on-year and by 15% since the previous quarter
GLUE's P/B is 16% below its last 4 quarters average of 1.7

Efficiency

How efficient is Monte Rosa Therapeutics business performance
GLUE's ROE has dropped by 76% year-on-year and by 12% since the previous quarter
The ROIC has plunged by 64% YoY and by 14% from the previous quarter
Monte Rosa Therapeutics's ROA has decreased by 45% YoY and by 3.8% from the previous quarter

Dividends

What is GLUE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GLUE.

Financial health

How did Monte Rosa Therapeutics financials performed over time
GLUE's total assets is 134% greater than its total liabilities
The total liabilities has surged by 75% year-on-year but it has declined by 8% since the previous quarter
The company's current ratio has shrunk by 59% YoY and by 4.9% QoQ
The debt is 70% smaller than the equity
The debt to equity has soared by 58% YoY and by 15% from the previous quarter
The equity has declined by 37% year-on-year and by 15% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.